Synact Pharma: Q4 comment

Research Note

2020-02-11

10:10

As expected, Synact’s interim report for the fourth quarter included no surprises. We give a brief comment on the financial situation and the anticipated news flow going forward.

LS

Ludvig Svensson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.